In Brief: ConvaTec
This article was originally published in The Gray Sheet
ConvaTec: Bristol-Meyers Squibb subsidiary opens manufacturing facility in Shenzhen, China, to produce ostomy care products for the Chinese market. The facility, Squibb-ConvaTec Medical Products, is a joint venture with Shenzhen China Associated Guangshen Pharmaceutical Company. China has an estimated 200,000 ostomy patients, a number anticipated to grow due to a "rise in the occurrence and diagnosis of colorectal cancer," BMS states...
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.